HALO
HALOZYME THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$112.45
+2.53%Next report
Analyst consensus
- Next report date
- Nov 2, 2026
- EPS estimate
- $2.25
- Revenue estimate
- $482.3M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- $2.28
- EPS estimate
- $1.79
- Revenue actual
- $481.0M
- Revenue estimate
- $402.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -18.1%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $104
- PT range
- $93 – $115
- Analysts
- 5
4 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | $1.79 | $2.28 | Beat 27.37% | $481.0M |
| May 11, 2026 | $1.54 | $1.60 | Beat 3.90% | $376.7M |
| Feb 17, 2026 | $2.15 | -$0.24 | Miss -111.16% | $451.8M |
| Feb 18, 2025 | $1.17 | $1.26 | Beat 7.69% | $298.0M |
| Oct 31, 2024 | $0.98 | $1.27 | Beat 29.59% | $290.1M |
| Feb 20, 2024 | $0.83 | $0.82 | Miss -1.20% | $230.0M |
| Feb 21, 2023 | $0.47 | $0.48 | Beat 2.13% | $181.5M |
| Feb 22, 2022 | $0.41 | $0.42 | Beat 2.44% | $102.0M |
| Nov 2, 2021 | $0.42 | $0.55 | Beat 30.95% | $115.8M |
| Feb 23, 2021 | $0.53 | $0.50 | Miss -5.66% | $121.7M |
| Feb 24, 2020 | -$0.18 | -$0.24 | Miss -33.33% | $53.7M |
| May 7, 2019 | $0.01 | $0.01 | Miss -28.06% | $56.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 2, 2026